HDHans Dieplinger

Hans Dieplinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hans Dieplinger has a total of 195 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lipoprotein(a) assembly–diagnostic and therapeutic implications

    by Benjamin Dieplinger, Hans Dieplinger

    This review summarizes our current knowledge and understanding of the biosynthesis and assembly of lipoprotein(a) [Lp(a)] with a focus on diagnostic and therapeutic implications. Lp(a) is composed of a low-density lipoprotein (LDL)-like particle and the covalently bound apolipoprotein(a) [apo(a)]. Our understanding of the physiology and pathophysiology of the atherogenic Lp(a) has considerably increased over the past decades. The precise mechanisms regulating the biosynthesis, secretion, and assembly of Lp(a) have been extensively investigated but are, nevertheless, still incompletely understood or, at least, controversially discussed. Lp(a) plasma concentrations are mainly determined by synthesis and, to a minor extent, also by catabolism. Assembly of Lp(a) occurs in a complex 2-step procedure, starting with an intracellular non-covalent association between lysine-binding sites on apo(a) and lysine residues on apoB-100, the two major protein components of Lp(a). The final assembly of Lp(a) occurs extracellularly and/or transiently associated with the cell membrane by covalent disulfide bonding from newly synthesized apolipoprotein(a) and circulating LDL. Lp(a)-lowering therapies have been developed that specifically inhibit apo(a) biosynthesis and Lp(a) particle assembly. The inhibition of Lp(a) assembly raises interesting questions regarding the quantification of Lp(a) since it leads to the release of substantial amounts of LDL-unbound apo(a), which is co-measured by routine laboratory assays. The complex biosynthesis and assembly pathway of Lp(a) has been intensively investigated since its discovery more than 60 years ago. It is not only of basic-scientific interest but also concerns actual issues of diagnosis and therapy of elevated plasma concentrations of this enigmatic lipoprotein.


  • Open Access

    Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease

    by Niina Pitkänen, Armin Finkenstedt, Claudia Lamina, Markus Juonala, Mika Kähönen, Kari-Matti Mäkelä, Benjamin Dieplinger, Andre Viveiros, Andreas Melmer, Isabella Leitner, et al.

    Objectives: In the general population, increased afamin concentrations are associated with the prevalence and incidence of metabolic syndrome as well as type 2 diabetes. Although metabolic syndrome is commonly associated with nonalcoholic fatty liver disease (NAFLD), there exist no information on afamin and NAFLD. Methods: Afamin concentrations were cross-sectionally measured in 146 Austrian patients with NAFLD, in 45 patients without NAFLD, and in 292 age- and sex-matched healthy controls. Furthermore, the feasibility of afamin to predict incident NAFLD was evaluated in 1,434 adult participants in the population-based Cardiovascular Risk in Young Finns Study during a 10-year follow-up. Results: Median afamin concentrations were significantly higher in NAFLD patients (83.6 mg/L) than in patients without NAFLD (61.6 mg/L, p<0.0001) or in healthy controls (63.9 mg/L, p<0.0001). In age- and sex-adjusted logistic regression analyses a 10 mg/L increase of afamin was associated with a 1.5-fold increase of having NAFLD as compared with patients without NAFLD and the risk was even two-fold when compared with healthy controls. In the population-based cohort, afamin concentrations at baseline were significantly lower in participants without NAFLD (n=1,195) than in 239 participants who developed NAFLD (56.5 vs. 66.9 mg/L, p<0.0001) during the 10-year follow up, with highest afamin values observed in individuals developing severe forms of NAFLD. After adjustment for several potentially confounding parameters, afamin remained an independent predictor for the development of NAFLD (OR=1.37 [95% CI 1.23–1.54] per 10 mg/L increase, p<0.0001). Conclusions: Afamin concentrations are increased in patients with NAFLD and independently predict the development of NAFLD in a population-based cohort.


  • Open Access

    Serum Afamin a Novel Marker of Increased Hepatic Lipid Content

    by Timea Kurdiova, Miroslav Balaz, Zuzana Kovanicova, Erika Zemkova, Martin Kuzma, Vitazoslav Belan, Juraj Payer, Daniela Gasperikova, Hans Dieplinger, Barbara Ukropcova, et al.

    Aim: Afamin is a liver-produced glycoprotein, a potential early marker of metabolic syndrome. Here we investigated regulation of afamin in a course of the metabolic disease development and in response to 3-month exercise intervention.Methods: We measured whole-body insulin sensitivity (euglycemic hyperinsulinemic clamp), glucose tolerance, abdominal adiposity, hepatic lipid content (magnetic resonance imaging/spectroscopy), habitual physical activity (accelerometers) and serum afamin (enzyme-linked immunosorbent assay) in 71 middle-aged men with obesity, prediabetes and newly diagnosed type 2 diabetes. Effects of 3-month exercise were investigated in 22 overweight-to-obese middle-aged individuals (16M/6F).Results: Prediabetes and type 2 diabetes, but not obesity, were associated with increased serum afamin (p<0.001). Afamin correlated positively with hepatic lipids, fatty liver index and liver damage markers; with parameters of adiposity (waist circumference, %body fat, adipocyte diameter) and insulin resistance (fasting insulin, C-peptide, HOMA-IR; p<0.001 all). Moreover, afamin negatively correlated with whole-body insulin sensitivity (M-value/Insulin, p63% of its variability. Exercise-related changes in afamin were paralleled by reciprocal changes in insulinemia, insulin resistance and visceral adiposity. No significant change in hepatic lipid content was observed.Conclusions: Subjects with prediabetes and type 2 diabetes had the highest serum afamin levels. Afamin was more tightly related to hepatic lipid accumulation, liver damage and insulin resistance than to obesity.


  • Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

    by Marta Futema, Uma Ramaswami, Lukas Tichy, Martin P. Bogsrud, Kirsten B. Holven, Jeanine Roeters van Lennep, Albert Wiegman, Olivier S. Descamps, Anne De Leener, Elodie Fastre, et al.


  • Open Access

    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries

    by Uma Ramaswami, Marta Futema, Martin P. Bogsrud, Kirsten B. Holven, Jeanine Roeters van Lennep, Albert Wiegman, Olivier S. Descamps, Michal Vrablik, Tomas Freiberger, Hans Dieplinger, et al.


  • Open Access

    Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays

    by Hubert Scharnagl, Tatjana Stojakovic, Benjamin Dieplinger, Hans Dieplinger, Gertraud Erhart, Gerhard M. Kostner, Markus Herrmann, Winfried März, Tanja B. Grammer


  • Open Access

    Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally

    by Angela Köninger, Antonella Iannaccone, Ensar Hajder, Mirjam Frank, Boerge Schmidt, Ekkehard Schleussner, Rainer Kimmig, Alexandra Gellhaus, Hans Dieplinger

    Background: Patients suffering from polycystic ovary syndrome (PCOS) are often insulin resistant and at elevated risk for developing gestational diabetes mellitus (GDM). The aim of this study was to explore afamin, which can be determined preconceptionally to indicate patients who will subsequently develop GDM. Serum concentrations of afamin are altered in conditions of oxidative stress like insulin resistance (IR) and correlate with the gold standard of IR determination, the HOMA index.Methods: Afamin serum concentrations and the HOMA index were analyzedpost hocin 63 PCOS patients with live births. Patients were treated at Essen University Hospital, Germany, between 2009 and 2018. Mann–WhitneyUtest,Ttest, Spearman’s correlation, linear regression models and receiver-operating characteristic (ROC) analyses were performed for statistical analysis.Results: Patients who developed GDM showed significantly higher HOMA and serum afamin values before their pregnancy (P < 0.001, respectively). ROCs for afamin concentrations showed an area under the curve of 0.78 (95% confidence interval (CI) 0.65–0.90) and of 0.77 (95% CI 0.64–0.89) for the HOMA index. An afamin threshold of 88.6 mg/L distinguished between women who will develop GDM and those who will not with a sensitivity of 79.3% and a specificity of 79.4%. A HOMA index of 2.5 showed a sensitivity of 65.5% and a specificity of 88.2%.Conclusion: The HOMA index and its surrogate parameter afamin are able to identify pre-pregnant PCOS patients who are at risk to develop GDM. Serum afamin concentrations are independent of fasting status and therefore an easily determinable biomarker.


  • Open Access

    Afamin: an early predictor of preeclampsia

    by Angela Köninger, Antje Enekwe, Pawel Mach, Dimitrios Andrikos, Boerge Schmidt, Mirjam Frank, Cahit Birdir, Rainer Kimmig, Alexandra Gellhaus, Hans Dieplinger

    Purpose Oxidative stress is involved in the pathogenesis of hypertensive disorders such as preeclampsia (PE) and associated with the human vitamin E-binding protein afamin. The aim of this study was, therefore, to analyse afamin in the first trimester of patients developing PE later in pregnancy and in control subjects without pregnancy complications. Methods In this retrospective study, 137 serum samples from the first trimester of pregnancy were analysed in a case–control study design. 39 patients developed PE (10 patients with early-onset and 29 patients with late onset disease) and 98 women had an uncomplicated pregnancy. Mann–Whitney U test, t test, logistic regression and ROC analyses were performed for statistical evaluation. Results Pregnant women developing PE presented with higher afamin concentrations in the first trimester [median 101.81 mg/L; interquartile range (IQR) 88.94–113.26] compared to subjects with uncomplicated pregnancy (median 86.40; IQR 75.26–96.92; p < 0.001). After adjusting for confounders, the odds ratio per afamin standard deviation was 1.60 (95% CI: 1.04–2.58; p = 0.04). An afamin threshold concentration of 87.8 mg/L exhibited the best sensitivity (79.5%) and specificity (57.1%) in predicting PE. Subgroup analysis of early- and late-onset disease resulted in substantially higher afamin concentrations in women with developing late-onset PE compared to controls (p < 0.001) with an odds ratio per afamin standard deviation of 1.62 (95% CI: 0.98–2.70; p = 0.06). Conclusions Serum afamin concentrations are elevated in the first trimester among patients developing PE compared to controls. Substantial differences were observed mainly among patients with late-onset PE.